Elanco Animal Health is recommended as a buy due to a strong new product cycle and increasing adoption in clinics. Products like Zenrelia and Credelio Quattro are gaining significant market share, supporting double-digit revenue growth and margin expansion. Additionally, Befrena shows promising early demand despite supply constraints limiting near-term impact. The company's valuation at about 21 times forward earnings appears reasonable given accelerating earnings growth and improving margins from better product mix and productivity.
US public debt surpassed $40 trillion on August 19, driven by rising interest costs and ongoing federal deficits. Bitcoin surged toward $70,000 following Treasury buybacks that eased long-term yields. Former President Trump expressed willingness to c...
UiPath has surged 44% in the past three months but still trades at a discount compared to its sector in terms of P/E and PEG ratios. The company shows accelerating revenue and annual recurring revenue (ARR) growth, supported by increasing large custo...
Bernstein upgraded Analog Devices (ADI) from Market Perform to Outperform following the company's record Q3 revenue of $4.02 billion, a 39.2% increase year-over-year and the first quarter surpassing $4 billion. The growth is fueled by strong demand i...
While the S&P 500 dropped 0.69% on Tuesday, the Energy sector reached new all-time highs, leading the market with a 41.5% gain year-to-date. This outpaces the next-best sector, Technology, by over 20 percentage points. Meanwhile, the Health Care sect...
California American Water has submitted testimony supporting the Monterey Peninsula Water Management District's request to modify the cease-and-desist order that limits new water connections. The order, in place since 2009, restricts new connections ...
